美国食品药品监督管理局小组讨论了怀孕期间的SSRI风险, FDA panel discusses SSRI risks in pregnancy, but experts stress balancing benefits too.

美国食品药品监督管理局召开专家小组讨论使用SSRI (一种抗抑郁药) 孕期的风险. The FDA held a panel to discuss the risks of using SSRIs, a type of antidepressant, during pregnancy. 虽然小组的重点是潜在风险,但专家们感到关切的是,这些药物在治疗抑郁和焦虑方面的益处正被忽视。 While the panel focused on potential risks, experts are concerned that the benefits of these medications in treating depression and anxiety are being overlooked. 最近的研究显示,使用SRI的先天缺陷没有显著增加,未经治疗的心理健康状况可能构成严重风险。 Recent studies show no significant increase in birth defects with SSRI use, and untreated mental health conditions can pose serious risks. 专家们强调需要平衡兼顾的观点,既考虑风险,也考虑好处,以确保孕妇得到适当治疗。 Experts emphasize the need for a balanced view that considers both risks and benefits to ensure proper treatment for pregnant women.